Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
- 1 March 2021
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 57 (3) , 106297
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Cilag
- Meso Scale Diagnostics
This publication has 32 references indexed in Scilit:
- Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance dataEpidemiology and Infection, 2012
- Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in PakistanScandinavian Journal of Infectious Diseases, 2012
- Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic ReviewPLOS ONE, 2011
- An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the FutureAntimicrobial Agents and Chemotherapy, 2011
- Mycobacterium tuberculosis–Specific Cellular Immune Profiles Suggest Bacillary Persistence Decades after Spontaneous Cure in Untreated TuberculosisThe Journal of Infectious Diseases, 2010
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum SmearsAntimicrobial Agents and Chemotherapy, 2007
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Controversial topics in tuberculosisEuropean Respiratory Journal, 2004
- Idiosyncratic drug reactions: the reactive metabolite syndromesThe Lancet, 2000